Download Image
    
Share
  
Post
Zavegepant for COVID-19
1 study with 43 patients
Hospital Icon Control
Hospital Icon Zavegepant Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Zavegepant studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -168% Mortality -168% RCTs -168% Late -168% Favorszavegepant Favorscontrol
Zavegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist.
May 2
2024
 Amali et al., NCT04346615 BHV3500-203: Phase 2/3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Zavegepant (BHV-3500) Intranasal (IN) for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
168% higher mortality (p=0.4), 25% higher ICU admission (p=1), and 11% worse recovery (p=0.47). RCT 47 hospitalized COVID-19 patients in the USA showing no significant differences with zavegepant treatment.